Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia.
Charcoal hemoperfusion has long been used in chronic uremia as an adjunct or substitute for conventional hemodialysis. In this study a regular combination of hemoperfusion and hemodialysis was used to cut down the weekly substitutive sessions from 3 to 2. Ten RDT patients were treated with the reduced-time schedule for 5-56 weeks. Clinical and metabolic conditions remained stable in all patients and no sign of inadequate treatment appeared. Long-term charcoal hemoperfusion was confirmed to be a safe and risk-free procedure. No change in platelets, white cells, red cells, fibrinogen and other hematochemical parameters were detected.
D000328:Adult; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D005069:Evaluation Studies as Topic; D005260:Female; D006464:Hemoperfusion; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D014280:Triglycerides; D014527:Uric Acid; D014508:Urea; D002784:Cholesterol; D003404:Creatinine